原发性胃肠道恶性淋巴瘤术后生存期的影响因素及TNM分期对远期生存的预测价值分析被引量：1

Prognostic factors of postoperative survival in patients with primary gastrointestinal malignant lymphoma and the predictive value of TNM staging for long-term survival

暂未订购

导出

摘要目的探讨原发性胃肠道恶性淋巴瘤术后生存期的影响因素及TNM分期对远期生存的预测价值。方法纳入我院收治的原发性胃肠道恶性淋巴瘤患者102例,对患者临床资料进行回顾性分析。通过电话随访明确其术后5年内的生存情况与生存时间,采用Cox回归分析观察原发性胃肠道恶性淋巴瘤患者生存期的影响因素,利用Kaplan-Meier绘制生存曲线图分析TNM分期对患者生存期的预测价值。结果在102例患者中,死亡41例,占全部病例的40.20%;生存组无远处转移、TNM分期Ⅰ~Ⅱ期、Lugano分期Ⅰ~Ⅱ期占比高于死亡组,差异有统计学意义(P<0.05);以TNM进行分期时,患者Ⅰ期、Ⅱ期、Ⅲ期、Ⅳ期5年内的生存率分别为54.10%、21.31%、16.39%、8.20%。以Lugano进行分期时,患者Ⅰ期、Ⅱ期、ⅡE期、Ⅳ期5年内的生存率分别为52.46%、22.95%、13.11%、11.48%,经Cox回归分析提示远处转移、TNM分期、Lugano分期与患者生存期有关(P<0.05);TNM分期对患者远期生存率的预测优于Lugano分期。结论胃恶性淋巴瘤患者远期生存期的影响因素包括远处转移、TNM分期以及Lugano分期,与Lugano分期比较,TNM分期对远期生存期的预测效果更理想。 Objective The aim of this study was to explore the prognostic factors of postoperative survival of patients with primary gastrointestinal malignant lymphoma and the predictive value of TNM staging for long-term survival. Methods A total of102 patients with primary gastrointestinal malignant lymphoma admitted into our hospital were retrospectively analyzed. The survival and survival time of 5 years after operation were confirmed by telephone follow-up. Cox regression analysis was used to observe the survival factors of patients with primary gastrointestinal malignant lymphoma. The survival curve of Kaplan Meier was used to analyze the predictive value of TNM staging on survival time of patient. Results Among the 102 patients,61 survived and 41 died,accounting for 59. 80% and 40. 20%,respectively. There was no distant metastasis and TNM stage in the survival group. The proportion of stage I to stage II and Lugano was higher than that in the death group. The difference was statistically significant（ P 0. 05）. The Cox regression analysis showed that the distant metastasis,TNM stage and Lugano staging were positively related to patient death（ P 0.05）. Using TNM staging in patients with stage Ⅰ,Ⅱ,Ⅲ and Ⅳ of 5 years survival rates were 54. 10%,21. 31%,16. 39%,21.31%. Using of Lugano staging in patients with stage Ⅰ,Ⅱ,Ⅱ E and Ⅳ of 5 years survival rate were 52. 46%,22. 95%,13. 11%,11. 48%. The prediction of long-term survival rate by TN. Conclusion The factors affecting the long-term survival of patients with gastric malignant lymphoma include distant metastasis,TNM staging,and Lugano staging. Compared with Lugano staging,the predictive effect of TNM staging on the long term survival is more ideal.

作者刘玉王子安 LIU Yu;WANG Zian(Bengbu Medical College of Anhui Province,Bengbu 233030,China;Department of Oncology,First Affiliated Hospital of Bengbu Medical College)

机构地区安徽省蚌埠医学院安徽省蚌埠医学院第一附属医院肿瘤内科

出处《实用肿瘤学杂志》 CAS 2018年第4期315-319,共5页 Practical Oncology Journal

关键词胃肠道恶性淋巴瘤 TNM分期生存曲线影响因素 Malignant lymphoma of the gastrointestinal tract TNM staging Survival curve Influencing factors

分类号 R735.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献6

1单丽珠,宋腾,王华庆,陈海珠,李书苹.HBV感染弥漫大B细胞淋巴瘤的临床特点和预后分析[J].实用肿瘤杂志,2016,31(2):163-169. 被引量：9
2吴永芳,许春伟,崔淼,张博,邵云,王海艳,王怀涛,李晓兵,张彤.间变性大细胞淋巴瘤的临床病理特征合并文献复习[J].实用癌症杂志,2016,31(1):151-155. 被引量：4
3彭健宏,肖斌毅,李聪,张荣欣,陈功,李力人,卢震海,丁培荣,万德森,潘志忠,伍小军.外科治疗原发性恶性胃肠道淋巴瘤39例临床研究[J].广东医学,2017,38(4):527-530. 被引量：10
4陈海珠,宋腾,张会来,周世勇,钱正子,宋拯,胡歌,王华庆.原发性胃肠道弥漫大B细胞淋巴瘤195例的临床特征和预后分析[J].中华消化杂志,2016,36(8):519-525. 被引量：22
5陶一明,冯铁诚,王志明.原发性肝癌患者TNM分期与术后生存关系:SEER数据库分析[J].中国普通外科杂志,2016,25(7):952-956. 被引量：15
6张文珏,朱慧,周宗玫,冯勤付,陈东福,张红星,肖泽芬,王绿化.TNM分期在局限期小细胞肺癌预后评估中的价值[J].中华肿瘤杂志,2015,37(12):917-922. 被引量：15

二级参考文献59

1卢晓云,李运红,刘明东,张建武,吕瑛,陈隆典,徐肇敏,邹晓平.原发性胃肠道恶性淋巴瘤33例临床分析[J].中华消化内镜杂志,2006,23(6):433-435. 被引量：16
2StahelRA, GinsbergR, HavemannK, et al. Staging and prognostic factors in small cell lung cancer; a consensus report[J]. Lung Cancer, 1989, 5(4–6):119–126.
3GoldstrawP, CrowleyJ, ChanskyK, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours[J]. J Throac Oncol, 2007, 2(8):706–714.
4MountainCF. A new international staging system for lung cancer[J]. Chest, 1986, 89(4Suppl):225S–233S.
5MickeP, FaldumA, MetzT, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer: what limits limited disease?[J]. Lung Cancer, 2002, 37(3):271–276.
6Ignatius OuSH, ZellJA. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition[J]. J Thorac Oncol, 2009, 4(3):300–310.
7VallièresE, ShepherdFA, CrowleyJ,et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer[J]. J Thorac Oncol, 2009, 4(9):1049–1059.
8BrinkI, SchumacherT, MixM, et al. Impact of [18F]FDG–PET on the primary staging of small–cell lung cancer[J]. Eur J Nucl Med Mol Imaging, 2004, 31(12):1614–1620.
9AupérinA, ArriagadaR, PignonJP, et al. Prophylactic cranial irradiation for patients with small–cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group[J]. N Engl J Med, 1999, 341(7):476–484.
10Le PéchouxC, LaplancheA, Faivre–FinnC, et al. Clinical neurological outcome and quality of life among patients with limited small–cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase Ⅲ trial (PCI99–01, EORTC 22003–08004, RTOG 0212 and IFCT 99–01)[J]. Ann Oncol, 2011, 22(5):1154–1163.